Logo image of THRD

THIRD HARMONIC BIO INC (THRD) Stock Fundamental Analysis

NASDAQ:THRD - Nasdaq - US88427A1079 - Common Stock - Currency: USD

3.25  -1.4 (-30.11%)

After market: 3.26 +0.01 (+0.31%)

Fundamental Rating

3

Overall THRD gets a fundamental rating of 3 out of 10. We evaluated THRD against 195 industry peers in the Pharmaceuticals industry. While THRD has a great health rating, there are worries on its profitability. THRD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year THRD has reported negative net income.
THRD had a negative operating cash flow in the past year.
THRD Yearly Net Income VS EBIT VS OCF VS FCFTHRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -12.87%, THRD is in the better half of the industry, outperforming 68.82% of the companies in the same industry.
The Return On Equity of THRD (-13.29%) is better than 74.73% of its industry peers.
Industry RankSector Rank
ROA -12.87%
ROE -13.29%
ROIC N/A
ROA(3y)-15.26%
ROA(5y)N/A
ROE(3y)-15.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THRD Yearly ROA, ROE, ROICTHRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -1K -2K -3K -4K

1.3 Margins

THRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THRD Yearly Profit, Operating, Gross MarginsTHRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

THRD has more shares outstanding than it did 1 year ago.
There is no outstanding debt for THRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
THRD Yearly Shares OutstandingTHRD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M
THRD Yearly Total Debt VS Total AssetsTHRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

THRD has an Altman-Z score of 12.95. This indicates that THRD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of THRD (12.95) is better than 88.71% of its industry peers.
There is no outstanding debt for THRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.95
ROIC/WACCN/A
WACCN/A
THRD Yearly LT Debt VS Equity VS FCFTHRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

THRD has a Current Ratio of 42.50. This indicates that THRD is financially healthy and has no problem in meeting its short term obligations.
THRD has a better Current ratio (42.50) than 99.46% of its industry peers.
A Quick Ratio of 42.50 indicates that THRD has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 42.50, THRD belongs to the best of the industry, outperforming 99.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 42.5
Quick Ratio 42.5
THRD Yearly Current Assets VS Current LiabilitesTHRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.79% over the past year.
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -13.31% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-24.28%
EPS Next 2Y-26.16%
EPS Next 3Y-22.85%
EPS Next 5Y-13.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THRD Yearly Revenue VS EstimatesTHRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
THRD Yearly EPS VS EstimatesTHRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for THRD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THRD Price Earnings VS Forward Price EarningsTHRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THRD Per share dataTHRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as THRD's earnings are expected to decrease with -22.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.16%
EPS Next 3Y-22.85%

More info and screens

0

5. Dividend

5.1 Amount

THRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THIRD HARMONIC BIO INC

NASDAQ:THRD (2/11/2025, 8:00:01 PM)

After market: 3.26 +0.01 (+0.31%)

3.25

-1.4 (-30.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners82.77%
Inst Owner Change-57.14%
Ins Owners3.49%
Ins Owner Change-12.38%
Market Cap146.44M
Analysts81.67
Price Target17.34 (433.54%)
Short Float %10.92%
Short Ratio14.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.31%
Min EPS beat(2)-8.2%
Max EPS beat(2)5.59%
EPS beat(4)3
Avg EPS beat(4)20.04%
Min EPS beat(4)-8.2%
Max EPS beat(4)46.24%
EPS beat(8)6
Avg EPS beat(8)20.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.53%
PT rev (3m)-10.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.43%
EPS NY rev (1m)-5.55%
EPS NY rev (3m)-4.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS6.54
TBVpS6.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.87%
ROE -13.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.26%
ROA(5y)N/A
ROE(3y)-15.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.96%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 42.5
Quick Ratio 42.5
Altman-Z 12.95
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.68%
EPS Next Y-24.28%
EPS Next 2Y-26.16%
EPS Next 3Y-22.85%
EPS Next 5Y-13.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.67%
EBIT Next 3Y-25.88%
EBIT Next 5Y-26.56%
FCF growth 1Y41.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.51%
OCF growth 3YN/A
OCF growth 5YN/A